Feb 10, 2004 (financialwire.net via COMTEX) -- (FinancialWire) Centrex (OTCBB:
CNEX) traded up 32.84% to close at $0.089 Monday on volume of 11,446,690, or 12
times its average volume of $991,016, following an announcement that Micronics,
Inc. has advanced the development of an assay that contains Centrex's single
molecule nucleic acid detection technology for application in a
laboratory-on-a-card format.
Micronics reported to Centrex that it has achieved the initial milestone which
permits lysis and binding reactions in the lab card format.
The company said SMD technology, in combination with an easy-to-operate lab card
device and integrated reader, is expected to be responsive to the need for
rapid, user friendly and cost effective solutions for point-of-use analyses of a
variety of bacterial and viral organisms.
Centrex's SMD technology was exclusively licensed from Los Alamos National
Laboratories, and offers important advantages over existing DNA and RNA
detection methods as well as culture-based test methods. SMD technology
eliminates the need for amplification of the target DNA by recognizing the
unique DNA or RNA fingerprint of the target organism. This reduces the
possibility of false positive and negative test results - common concerns
frequently identified with other test procedures.
As a next step in the development process, Micronics is expected to integrate
the lysing/binding reactions together with SMD using a biological stimulant, the
spores of the bacteria Bacillus globigii. Bacillus globigii prepared in this
manner may be used safely to simulate Bacillus anthracis (anthrax) spores in the
DNA extraction and binding experiments.
Centrex was enrolled in Investrend Research's unique and pioneering professional
analyst program, which facilitates independent analysts to provide financial
coverage for shareholders and investors in companies that otherwise would have
little or no analyst following, but its coverage is presently suspended due to
the company's failure to provide access to the analyst as required by the issuer
standards of the Association for Investment Management and Research.
The Investrend Research program is the largest in the world and includes a
number of safeguards to reduce or eliminate conflict. These systems, including
media coverage and endorsements, may be accessed at
www.investrendresearch.com
Investrend Research is a member of the FIRST Research Consortium at
www.firstresearchconsortium.com, and participates in the organization's
standards development panel for independent research providers. The
"Standards for Independent Research Providers" may be viewed at
www.investrend.com/Admin/Topics/Articles/...871_1060440861.doc
The Dow Jones (NYSE: DJ) Newswires has stated that independent research has been
growing in credibility over the past 18 months, specifically citing Investrend
Research, and the New York Times (NYSE: NYT) has reported a survey by Charles
Schwab & Co. (NYSE: SCH) reveals an astonishing 78 percent of active
stockholders now "value research from independent firms over analysis by
Wall Street firms with financial ties to the companies they are rating." A
survey at Investopedia reveals that 74.7% of investors say that "legitimate
fee-based research is objective and useful," and 70.9% say that a company that
enrolls for "legitimate fee-based research is making a positive statement
about its investment potential."
Enrollment fees for Institutional coverage were $23,400, and the fees were paid
by the company. There is an open invoice for $13,700 remaining on account. There
are never any fees associated with FinancialWire, which independently covers a
wide range of corporate news, including but not limited to those that are or
have been enrolled in Investrend's platforms.
Complete information about any company enrolled in an Investrend shareholder
empowerment platform, including those of its affiliates and independent analysts
and webcasters, including disclosures and disclaimers, is available at the
company's InvestorPower page at
www.investrend.com/company/list.asp?sPathParam=yes , and on each report
and press release, and investors are advised to read those disclosures carefully
before trading in the equities of any enrolled company.
For up-to-the-minute news, features and links click on
www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: www.investrend.com/XmlFeeds?level=268
URL: www.financialwire.net
(C) 2004 financialwire.net, Inc. All rights reserved.
Werbung
